Back to top
more

Labcorp (LH)

(Real Time Quote from BATS)

$198.52 USD

198.52
1,198,705

-9.42 (-4.53%)

Updated Apr 25, 2024 02:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View

Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.

Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Urmimala Biswas headshot

Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?

Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.

Merit Medical (MMSI) Earnings Expected to Grow: Should You Buy?

Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exploring Analyst Estimates for Labcorp (LH) Q1 Earnings, Beyond Revenue and EPS

Get a deeper insight into the potential performance of Labcorp (LH) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Nalak Das headshot

5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings

We have narrowed our search to five S&P 500 medical stocks that are poised to beat on first-quarter earnings results.These are: HCA, UHS, LH, EW, PODD.

Labcorp (LH) Expected to Beat Earnings Estimates: Should You Buy? (Revised)

Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Labcorp (LH) Could Beat Earnings Estimates Again

Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Labcorp (LH) Expected to Beat Earnings Estimates: Should You Buy?

Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LH vs. COO: Which Stock Should Value Investors Buy Now?

LH vs. COO: Which Stock Is the Better Value Option?

Should Value Investors Buy Labcorp (LH) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Labcorp (LH) to Report Q1 Earnings: What's in the Cards?

Labcorp (LH) is anticipated to drive growth in the first quarter of 2024 through base business expansion, integrating acquisitions and partnerships and advancing in science and technology.

Labcorp's (LH) At-Home Mpox Testing Kit Gets the FDA's EUA Nod

Labcorp (LH) receives the FDA's Emergency Use Authorization for the Mpox PCR Test Home Collection Kit.

Myriad Genetics (MYGN) Announces Favorable Research Results

Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.

Labcorp's (LH) Strategic Alliances Aid Amid Macroeconomic Woes

Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.

Labcorp (LH) Extends MRD Clinical Research With New Launch

Labcorp (LH) Plasma Detect MRD solution advances its leadership in precision oncology across the solid tumor oncology care continuum.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.

OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp

OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.

Labcorp (LH) to Boost Clinical Diagnostics With New Deal

The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.

Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test

Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.

Labcorp (LH) Presents New Research on Precision Diagnostics

Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.

Labcorp (LH) Expands Strategic Alliances, Test Sales Fall

Labcorp (LH) continues to progress in terms of integrating hospital partnerships and acquisitions.

LH or COO: Which Is the Better Value Stock Right Now?

LH vs. COO: Which Stock Is the Better Value Option?

Are Investors Undervaluing Labcorp (LH) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Labcorp (LH) Introduces Weight Loss Management Portfolio

Labcorp's (LH) Weight Loss Management service includes proven tests from its extensive menu and simplifies the procedure for both physicians and patients.